Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer

Yoshiko Urata, Isamu Okamoto, Masayuki Takeda, Yoshihiro Hattori, Keiko Okuno, Temiko Shimada, Takayasu Kurata, Hiroyasu Kaneda, Masaki Miyazaki, Masaaki Terashima, Kaoru Tanaka, Satoshi Morita, Kazuhiko Nakagawa, Shunichi Negoro, Miyako Satouchi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

background A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. methods Patients received carboplatin (area under the concentration-time curve, 5 mg mL-1 per minute) and bevacizumab (15 mg/kg) on day 1 plus oral S-1 (80 mg/m2 per day) on days 1 through 14 every 21 days for up to 6 cycles. For patients without disease progression, S-1 and bevacizumab were continued until disease progression or unacceptable toxicity developed. results Forty-eight patients were enrolled in the phase 2 study; of these, 35 patients (72.9%) completed at least 4 cycles. Most toxicities of grade ≥3 were hematologic, and no increase in relative incidence associated with maintenance with S-1 and bevacizumab was observed. The objective response rate was 54.2% (95% confidence interval, 39.2%-68.6%), and the median progression-free survival was 6.8 months (95% confidence interval, 4.3-8.2 months). conclusions The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC.

Original languageEnglish
Pages (from-to)2275-2281
Number of pages7
JournalCancer
Volume119
Issue number12
DOIs
Publication statusPublished - Jun 15 2013

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this